Lung cancer, a major cause of cancer-related mortality worldwide, develops when abnormal cells in the lungs proliferate uncontrollably, forming malignant tumors that impair respiratory function. It primarily manifests in two main types: Non-Small Cell Lung Cancer (NSCLC), which accounts for about 85% of cases and includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and Small Cell Lung Cancer (SCLC), a less common yet highly aggressive form characterized by rapid growth and early metastasis. The staging of lung cancer, crucial for determining prognosis and treatment, relies on the TNM system, which evaluates the size and extent of the primary tumor (T), involvement of regional lymph nodes (N), and presence of distant metastases (M). NSCLC is categorized from Stage 0, where cancer cells are confined to the airway lining without invasion or spread, to Stage IV, which indicates widespread metastasis to distant organs like the brain or liver, with treatments ranging from surgery and localized therapies in early stages to chemotherapy, targeted therapy, immunotherapy, and palliative care in advanced stages. Meanwhile, SCLC is typically divided into limited stage-where cancer is restricted to one lung and nearby lymph nodes and treated mainly with chemoradiation and preventive brain radiation-and extensive stage, which involves dissemination beyond the lung requiring systemic therapies and supportive care. This comprehensive classification system guides clinicians in tailoring interventions to improve outcomes for patients with lung cancer.

Lung cancer risk factors are broadly classified into modifiable and non-modifiable categories, with smoking being the predominant modifiable risk factor responsible for 8090% of cases, including both active smoking and secondhand smoke exposure. Other significant modifiable risks include prolonged exposure to radon gas a naturally occurring radioactive substance and the second leading cause in non-smokers and occupational hazards such as asbestos, silica, and diesel exhaust, common in industries like construction and mining. Air pollution, particularly fine particulate matter (PM2.5), and pre-existing lung diseases like chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis also elevate risk, while poor dietary habits may contribute indirectly. Non-modifiable factors include a family history of lung cancer, advancing age (especially beyond 65 years), specific genetic mutations like EGFR, ALK, or KRAS that increase susceptibility, and gender differences, with non-smoking women at higher risk than non-smoking men. Additional contributors encompass previous chest radiation therapy for other cancers, continuous secondhand smoke exposure, HIV infection due to immune compromise and higher smoking rates, and in certain geographic areas, arsenic contamination in drinking water, all of which compound the risk of developing lung cancer.

Lung cancer symptoms often begin subtly and worsen over time, with a persistent cough that fails to resolve or progressively intensifies, sometimes mistaken as a "smokers cough" in smokers. Early signs also include coughing up blood (hemoptysis), even in small amounts, shortness of breath or wheezing particularly during exertion, and chest pain that can be sharp or dull, worsening with deep breaths, coughing, or laughter. Patients may notice hoarseness or changes in voice, along with systemic symptoms like fatigue, unexplained weight loss, loss of appetite, and frequent respiratory infections such as recurrent pneumonia or bronchitis that do not fully respond to treatment. As lung cancer advances and metastasizes, additional symptoms emerge depending on the spread: bone pain from skeletal involvement, neurological issues such as headaches, dizziness, seizures, or limb weakness from brain metastases, swelling in the face, neck, or upper chest caused by superior vena cava syndrome due to tumor compression, jaundice if the liver is affected, and rare signs like Horners syndrome, characterized by drooping eyelid and pupil constriction. Finger clubbing, an enlargement of the fingertips linked to chronic low oxygen levels, may also be present, collectively highlighting the diverse and often severe clinical manifestations of lung cancer.

Diagnosing lung cancer involves a comprehensive approach beginning with a detailed medical history and physical examination, where the physician assesses symptoms, smoking and family history, occupational exposures, and performs a general physical check for signs like wheezing, swollen lymph nodes, or chest abnormalities. Imaging tests play a crucial role, starting with a chest X-ray to detect obvious masses or fluid, though it may miss small tumors, followed by more detailed cross-sectional imaging via CT scans to evaluate tumor size, shape, and spread, and PET scans that utilize radioactive sugar uptake to pinpoint active cancer cells, often combined with CT for enhanced accuracy. MRI scans help identify metastases in the brain or spinal cord, while bone scans assess potential bone involvement. Laboratory tests include sputum cytology to detect cancer cells in mucus, particularly for central lung cancers, and blood tests such as complete blood counts, liver and kidney function assessments, and tumor markers like CEA or CYFRA-21-1 to aid diagnosis and monitoring. Definitive diagnosis requires biopsy procedures where tissue samples are obtained through bronchoscopy, needle biopsies guided by imaging, mediastinoscopy for lymph node evaluation, thoracentesis for analyzing pleural fluid, or surgical biopsies (thoracoscopy or thoracotomy) if less invasive methods are inconclusive. Finally, molecular and genetic testing is increasingly vital to identify specific mutations (e.g., EGFR, ALK, KRAS) and biomarkers such as PD-L1, enabling personalized treatment strategies including targeted therapies and immunotherapy, thereby optimizing patient outcomes.

Treatment of lung cancer varies significantly based on the type and stage of the disease, beginning with Non-Small Cell Lung Cancer (NSCLC), where early-stage (Stage I) patients often undergo surgery such as lobectomy or segmentectomy to remove tumors, with radiation therapy as an alternative for those unfit for surgery, and adjuvant chemotherapy considered to reduce recurrence risk. Stage II similarly involves surgery combined with chemotherapy, and radiation if surgery is not feasible. In Stage III, locally advanced disease is treated primarily with chemoradiation, sometimes followed by surgery, and targeted therapies are employed for tumors with specific genetic mutations like EGFR or ALK. For metastatic Stage IV NSCLC, systemic treatments dominate, including targeted drugs such as osimertinib for EGFR mutations or alectinib for ALK alterations, immunotherapies like pembrolizumab targeting PD-L1 expression, and platinum-based chemotherapy; palliative care focuses on symptom relief. Small Cell Lung Cancer (SCLC) treatment is divided into limited and extensive stages, with limited disease managed by concurrent chemoradiation (typically cisplatin or carboplatin with etoposide), accompanied by prophylactic cranial irradiation to prevent brain metastasis, while extensive stage relies on chemotherapy often combined with immunotherapy agents like atezolizumab or durvalumab, with radiation used for symptom control. Common treatment modalities across lung cancer include surgical procedures such as lobectomy, pneumonectomy, and segmentectomy, radiation therapies like External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT), chemotherapy mainly with platinum-based regimens, targeted therapies tailored to genetic mutations (e.g., EGFR inhibitors osimertinib, ALK inhibitors alectinib, KRAS inhibitor sotorasib), and immunotherapies that harness the immune system to combat cancer cells. Palliative care is integral for advanced cases to manage pain, breathing difficulties, and psychological support, complemented by lifestyle interventions such as smoking cessation, nutritional support, and physical therapy. Additionally, clinical trials offer access to cutting-edge treatments and novel drug combinations, potentially improving patient outcomes.

Reducing the risk of lung cancer involves a multifaceted approach focused primarily on avoiding tobacco exposure, the most significant preventable cause, by quitting smoking through support programs, medications, and counseling, while also minimizing secondhand smoke exposure by promoting smoke-free environments at home and work. Testing homes for radon gas especially in high-risk areas and installing mitigation systems when elevated levels are detected can prevent this second-leading cause of lung cancer. Occupational risk reduction is essential, requiring the consistent use of protective equipment and strict adherence to workplace safety guidelines to limit exposure to carcinogens such as asbestos, silica, and diesel exhaust. Improving air quality by advocating for clean energy, reducing pollution, and using indoor air purifiers further lowers risk. A healthy diet rich in antioxidants from fruits, vegetables, and whole grains may help protect lung tissue, while avoiding high-dose beta-carotene supplements is advised, particularly for smokers. Regular physical activity supports lung health and decreases cancer risk. For individuals at high risk, such as heavy smokers aged 5080, participation in low-dose CT screening programs facilitates early detection. Additionally, ensuring safe drinking water by testing and treating arsenic contamination is vital in certain regions. Vaccinations against respiratory infections like influenza and pneumonia help maintain lung health, indirectly supporting cancer prevention. Lastly, genetic counseling for those with a family history of lung cancer provides personalized risk assessment and guidance on preventive strategies, empowering individuals to take proactive measures against lung cancer development.

Lung cancer research is a dynamic and rapidly advancing field dedicated to unraveling the complex biology of the disease, which includes studying genetic mutations, tumor microenvironments, and mechanisms of cancer progression and resistance. Scientists are focusing heavily on enhancing early detection methods and screening techniques, such as refining low-dose CT scans and developing novel biomarkers that could identify lung cancer at its most treatable stages. Concurrently, research efforts are aimed at creating more personalized and effective treatment options, including targeted therapies tailored to specific genetic alterations, next-generation immunotherapies, and combination treatment strategies that improve response rates and minimize side effects. Innovations in precision medicine and molecular diagnostics are transforming patient care by enabling more accurate prognoses and individualized treatment plans. These advances not only aim to increase survival rates but also seek to enhance patients quality of life by reducing treatment-related toxicity. Overall, the ongoing research holds significant promise for revolutionizing lung cancer prevention, detection, and therapy, providing renewed hope for patients worldwide.

1. What is lung cancer? Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These cells can form tumors that interfere with breathing and normal lung function. There are two main types: Non-Small Cell Lung Cancer (NSCLC), which is more common, and Small Cell Lung Cancer (SCLC), which is more aggressive and spreads faster. 2. What are the main causes of lung cancer? The leading cause of lung cancer is smoking-both active smoking and exposure to secondhand smoke-accounting for over 80% of cases. Other contributing factors include exposure to radon gas, air pollution, asbestos, certain occupational chemicals, and genetic mutations. 3. What are the symptoms of lung cancer? Lung cancer symptoms often appear in later stages and may include a persistent cough, shortness of breath, chest pain, coughing up blood, unexplained weight loss, fatigue, hoarseness, and frequent respiratory infections. 4. Who is at risk for lung cancer? People at higher risk include smokers and former smokers, individuals exposed to secondhand smoke, those with a family history of lung cancer, and people exposed to radon gas, asbestos, or other carcinogens. Living in areas with high air pollution also increases the risk. 5. Can nonsmokers get lung cancer? Yes. Although smoking is the primary risk factor, nonsmokers can develop lung cancer due to exposure to radon, air pollution, secondhand smoke, genetic mutations, or hazardous substances in certain workplaces.